DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
Saxenda (liraglutide 3.0mg) is a daily injection FDA-approved for chronic weight management.
A proven but now-dated daily GLP-1 option
Saxenda was the first GLP-1 approved purely for weight loss, and the clinical evidence behind it is solid: roughly 8% average body-weight reduction at 56 weeks in the SCALE trial. But it requires a daily injection and, in a head-to-head trial, delivered less than half the weight loss of weekly semaglutide. For most new patients in 2026, it is a second-tier choice unless a daily liraglutide is specifically preferred, better covered, or available more cheaply as a generic. This is general information, not medical advice.
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
Saxenda is a brand-name injectable form of liraglutide, made by Novo Nordisk, dosed at 3.0 mg once daily. The FDA first approved it in December 2014 for chronic weight management (FDA). It is the same molecule as Victoza — Novo Nordisk's older diabetes drug — but at a higher dose and approved for a different purpose.
Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related condition such as high blood pressure, type 2 diabetes, or dyslipidemia (FDA label). In December 2020, the FDA expanded the indication to adolescents aged 12–17 with obesity who weigh more than 60 kg (FDA).
The key phrase is "chronic." Saxenda is studied and labeled as a long-term therapy, not a short detox course. When the drug is stopped, appetite and weight typically return — a pattern observed consistently across the GLP-1 class.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a natural gut hormone, GLP-1, that the body releases after eating. By activating GLP-1 receptors, it works through several mechanisms relevant to weight:
The net effect is that most people simply eat less without consciously trying as hard. Importantly, liraglutide is a short-acting GLP-1 relative to newer agents: it has a half-life of around 13 hours, which is why it must be injected every single day to maintain effect. This is the single biggest practical difference between Saxenda and the once-weekly drugs that have since eclipsed it.
The pivotal evidence comes from the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015; PMID 26132939), a 56-week randomized controlled trial of 3,731 adults without diabetes. The numbers:
For context, a 5–10% loss is the threshold clinicians associate with meaningful improvements in blood pressure, blood sugar, and cardiometabolic risk — so these are clinically real results, not cosmetic. Saxenda also improved markers like fasting glucose and reduced progression to type 2 diabetes in the prediabetes population.
In people who already have type 2 diabetes, weight loss is typically more modest. The SCALE Diabetes trial (Davies et al., JAMA 2015) found smaller average reductions than in the non-diabetic population — a consistent pattern across GLP-1 weight studies.
Two caveats matter. First, the "average" hides wide variation: a meaningful subset of people lose little. The FDA Saxenda label specifically instructs prescribers to evaluate weight 16 weeks after starting and to discontinue the drug if a person has not lost at least 4% of baseline body weight, because continued clinically meaningful response becomes unlikely (FDA label). Second, almost all weight regains after stopping. Saxenda is best understood as ongoing treatment of a chronic condition, not a cure.
Saxenda is a once-daily subcutaneous injection given with a prefilled multi-dose pen, into the abdomen, thigh, or upper arm, at any time of day, with or without food. To reduce gastrointestinal side effects, the dose is escalated slowly over five weeks (FDA label):
If a person cannot tolerate a dose step, the titration can be paused or slowed. If the 3.0 mg dose is not tolerated, discontinuation is advised rather than staying at a lower dose long-term, since lower doses are not established as effective for weight management. A missed dose is simply skipped — the schedule is not doubled up.
The most common adverse effects are gastrointestinal and largely concentrated during dose escalation: nausea, diarrhea, constipation, vomiting, abdominal pain, indigestion, and decreased appetite (FDA label). Nausea was the standout in trials. These are usually mild to moderate and tend to ease over time, and slow titration plus smaller meals helps. Headache, dizziness, fatigue, and injection-site reactions also occur.
Saxenda carries an FDA boxed warning — the agency's most serious — because liraglutide caused thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in rodents at clinically relevant exposures. Whether this risk translates to humans is unknown (FDA label). Because of this, Saxenda is contraindicated in people with a personal or family history of MTC and in those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled to report neck masses, difficulty swallowing, shortness of breath, or persistent hoarseness.
Because Saxenda delays gastric emptying, it can affect the absorption of oral medications taken at the same time. Caution applies to drugs where rapid absorption matters. Combination with insulin or insulin secretagogues increases hypoglycemia risk. People should review their full medication list with a prescriber.
It may be a reasonable option for someone who:
It's a poor fit — or contraindicated — for someone who:
Saxenda is a prescription medication, and its list price is high: about $1,349 per month for the standard supply of five pens at the 3.0 mg dose (Novo Nordisk/NovoCare). Most people do not pay full list price, but actual out-of-pocket cost varies enormously:
A genuinely useful new development: the FDA approved the first generic liraglutide in late 2024 (FDA), and an authorized generic of the diabetes version (Victoza) also reached the market. Generic liraglutide should, over time, pressure prices downward. Note that initial generic approvals were tied to the diabetes indication/dosing; availability of a lower-cost liraglutide specifically marketed for weight management is still maturing, so ask a pharmacist what generic options apply to your situation.
This is where Saxenda's standing has shifted dramatically. It was a pioneer; it is no longer the strongest tool.
The practical takeaway: for raw efficacy and convenience, the once-weekly drugs win clearly. Saxenda's case rests on specific circumstances — coverage, the adolescent indication, the long track record, daily flexibility, or intolerance of the newer agents.
Saxenda is a legitimate, FDA-approved, evidence-backed weight-management medication. The SCALE data are solid: roughly 8% average weight loss, with about a third of users losing more than 10% of their body weight — clinically meaningful results that improve cardiometabolic risk. It has nearly a decade of real-world use behind it and a specific niche in adolescent obesity.
But in 2026, the honest assessment is that Saxenda has been outclassed on the two things people care about most: it requires a daily injection rather than a weekly one, and head-to-head data show it delivers less than half the weight loss of semaglutide and considerably less than tirzepatide. For most adults starting GLP-1 therapy with full access, a once-weekly agent is the stronger first choice. Saxenda makes the most sense when those newer drugs are unavailable, unaffordable, not tolerated, or inappropriate (such as in eligible adolescents), and the emerging availability of generic liraglutide could yet revive its value proposition on price. As with the entire class, the benefit lasts only as long as treatment does — so the decision is really about committing to long-term therapy, not a quick result. Anyone considering it should review the boxed warning, contraindications, and their full medication list with a qualified prescriber.
*This article is for informational purposes and is not medical advice. HealthVetted is independent, accepts no payment for placement, and sells none of the products it reviews. Consult a licensed clinician about your individual situation.*
Saxenda's active ingredient is liraglutide, a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a natural gut hormone released after eating. By activating GLP-1 receptors in the brain's appetite centers, it increases feelings of fullness and reduces hunger, which tends to lower how many calories you eat. It also slows stomach emptying, so food stays in the stomach longer. Because liraglutide is relatively short-acting, it must be injected once every day, unlike newer once-weekly GLP-1 drugs.
Active ingredient: Liraglutide
In the pivotal SCALE Obesity and Prediabetes trial (NEJM, 2015), adults without diabetes lost a mean of 8.0% of body weight on liraglutide 3.0 mg versus 2.6% on placebo at 56 weeks. About 63% of liraglutide patients lost at least 5% of body weight (vs. 27% on placebo) and roughly 33% lost at least 10% (vs. 11% on placebo). However, in the head-to-head STEP 8 trial (JAMA, 2022), once-weekly semaglutide 2.4 mg produced 15.8% mean weight loss versus 6.4% for daily liraglutide 3.0 mg over 68 weeks, more than double the effect. Individual results vary and depend heavily on combining the drug with diet and activity.
A realistic timeline of what Saxenda users typically experience. Individual results vary; this is educational, not medical advice.
Saxenda is a once-daily self-injection started low and stepped up to limit side effects: 0.6 mg in week 1, then +0.6 mg each week (1.2, 1.8, 2.4 mg) to reach the 3.0 mg maintenance dose by week 5. Most people don't see meaningful weight change yet; this phase is about building tolerance, per the FDA label.
Mild-to-moderate gastrointestinal effects are most common early and often flare with each dose increase: nausea (the most frequent), reduced appetite, early fullness, constipation or diarrhea, and sometimes vomiting. These typically ease over the first few weeks as the body adjusts; your prescriber may slow titration by a week if a dose isn't tolerated.
On the full 3 mg dose, appetite suppression and gradual weight loss usually become noticeable. Week 16 is a formal checkpoint in the prescribing information: if you haven't lost at least 4% of your starting body weight by then, the label advises stopping, since continued meaningful loss is unlikely. Results vary widely between individuals.
In the SCALE trial, adults on 3 mg plus a reduced-calorie diet and increased activity lost about 8.4% of body weight on average over 56 weeks, versus 2.8% on placebo. Saxenda works alongside lifestyle changes, not instead of them; weight tends to plateau over time, and individual results differ.
Saxenda is intended for long-term use under medical supervision, with periodic check-ins on dose tolerance, weight, and overall health. Weight regain is common if the medication is stopped, so any decision to continue, pause, or discontinue should be made with your prescriber.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain, typically mild-to-moderate and worst during the first weeks as the dose is increased. Headache, low blood sugar (especially in people with type 2 diabetes), increased heart rate, and injection-site reactions also occur. Serious but uncommon risks include acute pancreatitis, gallbladder disease (gallstones), and kidney problems from dehydration. Saxenda carries an FDA boxed warning for thyroid C-cell tumors based on rodent studies; whether this risk applies to humans is not known. Seek urgent medical care for severe, persistent abdominal pain, signs of an allergic reaction, or a lump or swelling in the neck.
Sourced from FDA labeling and clinical references; not exhaustive and not a substitute for your prescriber or pharmacist. Always disclose every medication and supplement you take.
Starts at $1349/mo from Novo Nordisk.
As of 2026, Saxenda's cash price without insurance runs roughly $1,300 to $1,650 per month for a 30-day supply (five prefilled pens), varying by pharmacy. Pharmacy discount coupons (e.g., GoodRx) can cut this to around $370-$500. Insurance coverage is inconsistent, often requires prior authorization, and many commercial plans, plus Medicare, exclude weight-loss drugs entirely. Note that Novo Nordisk's $25 Saxenda Savings Card was discontinued for new enrollees in mid-2023, so it is no longer a reliable way to lower cost; uninsured patients with limited income may instead qualify for free medication through the Novo Nordisk Patient Assistance Program. A lower-cost generic liraglutide (from Teva) launched in the US in 2025 at roughly $1,165 per month, which may reduce out-of-pocket costs over time as availability expands.
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
Saxenda genuinely works and has a decade of safety data behind liraglutide, but a head-to-head trial (STEP 8) showed it produced less than half the weight loss of weekly semaglutide. Combined with daily injections and a high cash price, it is hard to recommend as a first choice in 2026 unless cost, coverage, the new generic, or a clinician's judgment points to liraglutide specifically. Discuss newer weekly options with your prescriber before deciding.
In the pivotal SCALE trial, adults lost an average of about 8% of body weight at 56 weeks versus 2.6% on placebo. Roughly 63% lost at least 5% and about 33% lost at least 10%, when Saxenda was combined with a reduced-calorie diet and exercise. Individual results vary.
No. All three are GLP-1 receptor agonists, but Saxenda uses liraglutide injected once daily, while Wegovy and Ozempic use semaglutide injected once weekly. Wegovy is approved for weight loss; Ozempic is approved for type 2 diabetes (though it is sometimes prescribed off-label for weight).
Wegovy is more effective. In the head-to-head STEP 8 trial, weekly semaglutide 2.4 mg produced 15.8% average weight loss versus 6.4% for daily Saxenda over 68 weeks, more than double the result.
Nausea is the most common, along with vomiting, diarrhea, constipation, and abdominal pain. These are usually mild-to-moderate and most intense during the first weeks while the dose is being increased. Rare but serious risks include pancreatitis and gallbladder disease.
Without insurance, Saxenda typically costs about $1,300 to $1,650 per month. Discount coupons such as GoodRx can lower it to roughly $370-$500. The $25 Novo Nordisk savings card was discontinued for new enrollees, but a lower-cost generic liraglutide (around $1,165/month) became available in 2025, and a Novo Nordisk patient assistance program may help eligible low-income, uninsured patients.
Yes, weight regain is common after stopping, because Saxenda controls appetite only while you are taking it. Most clinicians treat it as a long-term therapy alongside sustained diet and lifestyle changes rather than a short course.
Avoid Saxenda if you have a personal or family history of medullary thyroid cancer (MTC) or MEN 2, are pregnant, or have had a serious allergic reaction to liraglutide. Use caution if you have a history of pancreatitis or gallbladder disease, and do not combine it with other GLP-1 medicines. Confirm with your doctor.
Saxenda is a once-daily injection under the skin of the abdomen, thigh, or upper arm. The dose is increased weekly from 0.6 mg, stepping up to 1.2, 1.8, and 2.4 mg, reaching the 3.0 mg maintenance dose by week 5, which helps reduce nausea.
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Legitimate ways to lower your cost. We don’t sell Saxenda — this is independent guidance, not medical or financial advice. Confirm current terms with the program and your clinician.
Many brand-name drugs have a manufacturer copay-savings program on the drug’s official site. Check the maker’s website for a current savings card (commercial insurance usually required; government insurance excluded).
If you’re uninsured or low-income, free or reduced-cost medication may be available through patient assistance programs. Search MedicineAssistanceTool (PhRMA) and NeedyMeds.
Filling a 90-day supply instead of monthly often lowers the per-month cost and cuts pharmacy trips. Ask your prescriber and pharmacy whether it’s an option for you.
A different formulation or product may cost less for a similar result. Compounded GLP-1 · Supplements vs GLP-1.
Same-category options, scored on the same six-axis rubric. Higher is better.